Background: Mutations of the epidermal growth factor receptor (EGFR) gene in non-small-cell lung cancer (NSCLC) patients predict the patients who will respond to EGFR tyrosine kinase inhibitor (TKI) treatment. A recent study has suggested that 33% of NSCLC showed primary tumor/metastasis discordance of EGFR expression by immunohistochemistry analysis. We intended to find out whether the EGFR mutations of primary lung cancers are concordant to that of corresponding metastatic tumors.
introduction
Epidermal growth factor receptor (EGFR), a member of the ErbB receptor family, is a transmembranal glycoprotein encoded by a gene located in the short arm of chromosome 7 [1] . Multiple ligands bind to the extracellular domain of the EGFR lead to initiate signal transduction cascades, which contribute to cell proliferation, antiapoptosis, angiogenesis, invasion, and metastasis [2] . There is a good deal of accumulated evidence that EGFR is strongly implicated in the development and progression of numerous tumors, including lung cancer.
Small molecular tyrosine kinase inhibitors (TKIs), gefitinib and erlotinib, disrupt EGFR kinase activity by binding the adenosine triphosphate pocket within the catalytic region of the tyrosine kinase domain [3] . Currently, both gefitinib and erlotinib are used for treatment of patients of advanced non-small-cell lung cancer (NSCLC) [4, 5] . The clinical response of NSCLC to EGFR TKIs is dramatic in some patients. Somatic mutations in the tyrosine kinase domain of the EGFR gene in NSCLC patients correlate to patients who have experienced significant tumor shrinkage with EGFR TKI [6] [7] [8] . Such mutations are more frequent among women, patients with adenocarcinoma, patients who have never been smokers, and East Asian patients, which is consistent with the known clinical predictors of TKI sensitivity [9] [10] [11] .
An emerging issue concerning TKI treatment in advanced disseminated NSCLC is to identify EGFR mutations, the best tool for selecting patients who will be candidates for clinical response [12] [13] [14] . Recent studies have suggested that EGFR expression is not stable during metastatic progression [15] [17] . Clinicopathologic staging was determined according to the International Union Against Cancer tumor-node-metastasis classification of malignant tumors [18] . The baseline characteristics of these 67 patients are listed in Table 1 . Most of the patients (60 of 67, 90%) had not received systemic chemotherapy or thoracic radiotherapy before surgical treatment of the primary lung cancer. None of the patients had received prior EGFR TKI therapy. Pathologic samples from 67 metastatic sites were analyzed and included 25 brain metastases (38%), 20 bone metastases (30%), and 22 other various metastatic sites (32%). The median time elapsed between resection of the primary and corresponding metastatic tumors was 9.3 months (0-90 months). None of the patients had received EGFR TKI therapy before resection of the metastatic tumors.
DNA extraction and mutational analyses
The adequacy of the material was checked by microscopy with hematoxylin and eosin staining on tissue sections and only tissue samples with >80% tumor content were studied. The mutational analysis of the EGFR gene was carried out as previously described [12] . Briefly, a total of four microsections of 10-lm thickness of the paraffin-embedded tissues from primary lung carcinomas, metastases, and normal lung (for internal control) tissues were obtained and genomic DNA was extracted using a QIAmp DNA Mini kit (Qiagen, Valencia, CA). The tyrosine kinase domain of the EGFR-coding sequence, exons 18, 19, 20, and 21, was amplified and PCR amplicons were purified and sequenced in an automatic ABI Prism 3700 DNA Analyzer. All sequencing reactions were carried out in both forward and reverse directions, using tracings from at least two independent PCRs. All cancer samples underwent the second round of microsections, DNA extractions, and independent PCRs in duplicate with forward and reverse sequencing to confirm the results. Mutations were also checked against the corresponding sequences from surgical adjacent nonneoplastic lung tissue DNA and single nucleotide polymorphism database. mutational analysis of discordant EGFR mutations using the Scorpion Amplified Refractory Mutation System method The 26 discordant EGFR mutations between primary and metastatic tumors by direct nucleotide sequencing were reanalyzed using the Scorpion Amplified Refractory Mutation System (SARMS) assay, which was conduced with the EGFR mutation test kit (DxS, Manchester, UK), to detect 29 specific mutations in the EGFR gene. The assay combined two technical methods, Scorpion and ARMS, to detect mutations in real-time PCRs. This kit enables the detection of the 19 distinguish deletions between 2235 and 2257 in exon 19, T790M, L858R, L861Q, G719X, S768I, and three insertions in exon 20. Assays were carried out according to the manufacturer's protocol and using the Applied Biosystem (ABI) 7500 realtime PCR system. Data analysis used the ABI SDS software. These PCRs were carried out in duplicate for each sample and two investigators blinded to any clinical information analyzed the results. 
results

EGFR gene mutation analysis using direct sequencing
We carried out the whole procedure of EGFR sequencing from tissue microsection to final direct sequencing in duplicate. One sample was found with a mutation in its first tissue microsection while not being detected in its second round of microsection was considered to be a PCR artifact. Finally, EGFR gene mutations were found in 18 of 67 (27%) primary lung tumors and 26 of 67 (39%) corresponding metastases ( Table 2 ). In total, EGFR mutations were found in 35 of 67 (52%) cases (Table 3) . We did not find any mutations in the corresponding DNA from normal lung tissues, confirming that these mutations were somatic in origin. The type and location of the mutations in paired tumors are shown in Table 3 . The majority of EGFR mutations of primary lung tumors were deletions in exon 19 (7 of 67, 10%) and point mutations in exon 21 (9 of 67, 13%). Analyses of the metastatic sites showed that EGFR mutations were detected in 11 brain metastases (11 of 25, 44%), seven bone metastases (7 of 20, 35%), and eight other various metastatic tumors (8 of 22, 36%). The most common EGFR mutations were also found with deletion in exon 19 (15 of 67, 22%) and L858R in exon 21 (9 of 67, 13%). In exon 20, a soft tissue with metastatic tumor harbored T790M and another metastatic bone tumor was detected with duplication of NPH771-773.
heterogeneity of EGFR mutation status in primary tumors and metastases by direct sequencing
The EGFR mutation status in the primary lung tumors and corresponding metastatic sites of each patient was not always identical (Table 3 ). In 18 patients with EGFR mutation-positive primary lung tumors, nine (50%) patients had lost the mutations in metastases. For 26 patients who were EGFR mutation positive in the metastatic tumors, 17 (65%) were negative in the primary tumors. There was a trend for this discordance (McNemar's test, P = 0.117).
Nine of 18 patients with EGFR mutation-positive primary lung tumors showed wild type in the metastatic sites (Table 3) . One distant lymph node lost a point mutation (Y727C) in exon 18. Four metastatic tumors lost in-flame deletions and four patients lost mutations in exon 21. Seventeen of 26 patients with EGFR mutations in the metastatic sites were wild type in the primary lung tumors. Of these gained mutations in metastatic sites, brain tumors were found in most of the cases (7 of 18), including six patients with deletions in exon 19 
Mutation analysis using the SARMS method
Twenty-six cases with discordant of EGFR mutation diagnosed by direct sequencing were reanalyzed using more sensitive SARMS assay. Ten of those 26 paired EGFR mutation status were identified as concordant by the SARMS method: two cases were not detected in both primary and metastatic tumors (numbers 10 and 15), seven cases showed exon 19 deletion in both sites (numbers 12, 13, 20, 22, 24, 26, and 28), and one case (number 32) with identical L858R in both of primary and metastatic tumors (Table 4) .
Discordant rate of EGFR mutations in primary/ metastatic sites
Sixteen mutations detected by SARMS assay between primary and corresponding metastatic sites were not identical. Another two rare point mutations (Y727C and D855N, case numbers 10 and 15, respectively), which could not be detected by SARMS assay, were found by direct sequencing and considered to be discordance (Table 4) . After combination of the results of direct sequencing and SARMS analyses, 18 discordant EGFR mutations were concluded in this study and the discordant rate reached 27% (18 of 67) (McNemar's test, P = 0.346).
discussion
This study was carried out to assess the agreement of EGFR mutations between the primary and corresponding metastatic tumors. We determined 67 pairs of primary lung tumors and metastases to evaluate whether EGFR mutations changed during disease progression. These data show that primary tumors, the easiest tissues to obtain for patient studies, are unlikely to give a clear representation of the EGFR mutation status of the metastatic tumors. Metastatic advanced lung cancer continues to represent a major health problem worldwide, while the introduction of agents directly against EGFR has notably expanded the available therapeutic options for these patients [19] . However, the majority of EGFR mutations are usually evaluated only in primary tumors because biopsy of metastatic sites is not routinely feasible. By examining the EGFR gene in metastatic tumors corresponding to primary lung tumors in our series, we suggest that EGFR mutations have a trend to differ between primary and metastatic tumors. This finding brings a new insight into the biology of EGFR-mutated NSCLC. This biological phenomenon of discordant EGFR mutations could partially account for the fact that some advanced NSCLC patients with wild-type EGFR respond to EGFR TKI and why some patients with well-known EGFR TKI-sensitive mutations fail to respond to EGFR TKI therapy.
In the majority of nonconcordant cases of this report, EGFR mutations were observed in the metastatic tumor while the corresponding primary tumor displayed wild type (11 of 18, 61%, Table 4 ). This result suggests that EGFR mutations may change during metastases after diagnosis of the primary tumors. Although the molecular basis for this disparity is not EGFR, epidermal growth factor receptor; ADC, adenocarcinoma; SQC, squamous cell carcinoma; LELC, lymphoepithelioma-like carcinoma; Del, deletion; ins, insertion; Dup, duplication.
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known, this has important clinical implications. With the development of anti-EGFR TKI therapy, EGFR mutation status has been proposed to guide patient selection. Previously, we have shown that fine needle biopsy/aspiration of metastatic tumors and pleural effusions are feasible for the detection of EGFR mutations [12] . Therefore, for better correlation of EGFR mutation status and responsiveness of EGFR TKI, biopsies of metastatic tumors, though difficult to obtain, should be pursued.
Whether the metastatic cancer cells arose from sequential divergence of the primary tumor or disseminated early in their genomic development is still unclear [20] . In previous studies, frequent genetic heterogeneities were found between primary tumors and corresponding metastatic sites by comparative genomic hybridization or loss of heterozygosity analysis [21, 22] . Discordance of genetic alteration between primary tumors and corresponding metastases was also observed in specific genes in several reports. For example, a significant discordance was found between bone marrow micrometastases and paired primary tumors in colorectal cancer patients based on the colonal analysis of the somatic mutations of the K-ras gene [23] . Albanese et al. [24] also demonstrated discordance rates of 61% in K-ras mutations and 33% in p53 mutations between primary colorectal carcinomas and matched metastases. In NSCLC, the expression of EGFR in primary tumor/metastasis showed a discordance rate of 33.3% by immunohistochemistry analysis [15] . Badalian et al. [25] studied matched bone metastases of NSCLC and primary tumors. Only 45.5% maintained EGFR protein expression while there was a 64% inconsistency in K-ras mutations. Furthermore, in a mixed adenocarcinoma lung nodule, different EGFR mutations were demonstrated in various parts of the tumor, which suggested that EGFR mutations may accumulate during tumor progression [16] . In our study, we explored the heterogeneity of EGFR mutations between paired primary/metastasis in lung cancer patients. The discordance between primary and metastatic tumors could be attributed to several models of metastatic progression. First, malignant tumors acquire the metastatic phenotype through the genetic drift or clonal selection for EGFR mutations during the multistep tumor progression, which may exist during tumor progression [26] . Secondly, clones containing enhanced metastatic potential of EGFR mutations in intratumoral heterogeneity of cancer tissues can lead to a different EGFR mutation status in metastatic sites from that of the primary tumors [16, 20] . Finally, the distant micrometastasis happened at a fairly early stage of NSCLC [27] , and this evolution process occurred original article Annals of Oncology during clonal selection before metastasis or occurred under a different environment after metastatic seeding [20] . Therefore, the genetic alteration in surgically sampled primary tumors and corresponding metastatic sites may reveal different characteristics. The present study also yielded a major finding: the SARMS assay may be more sensitive for detecting EGFR mutations than direct sequencing. Patients with EGFR mutations may be misdiagnosed as not having any mutation or unable to detect major mutations in a mixed tumor clones by nucleotide sequencing. In this study, two rare mutations were unable to be detected by the SARMS assay. So far, no literatures have applied the SARMS method to compare EGFR mutations between both sites. Even though the increased sensitivity using SARMS assay causes a less discordant rate, it still has a disagreement of 27% between primary and metastatic tumors. These discrepancies between methods may be attributed to techniques sensitivity, restricted known mutation by SARMS assay, quality of tumor-based sequencing analysis, or variable tumor clones in both sites [28] [29] [30] . Therefore, a large-scale study population is desired to further investigate this finding.
The main limitations in our study were tissue availability and the use of various metastatic sites. This is secondary to the fact that distant metastasis, in a patient with a known primary NSCLC, is rarely operable, and if done, it is usually for isolated brain metastasis resection or stability of weight-bearing bones through surgical procedures. Therefore, the metastatic tissues we studied did not include all the possible sites of NSCLC metastases.
In summary, we have shown that EGFR mutations in primary lung tumors do not always reflect the same situation in metastases. Since EGFR-targeted TKIs are used to treat metastatic disease, a more aggressive pursuit of tissue sampling from distant metastasis may be indicated to accurately determine EGFR mutations. Expanded studies with prospective clinical trials including EGFR TKI response and EGFR mutation analysis on metastases may be needed. 
